California State Teachers Retirement System cut its stake in Bioverativ Inc (NASDAQ:BIVV) by 1.5% in the fourth quarter, HoldingsChannel.com reports. The fund owned 171,878 shares of the biotechnology company’s stock after selling 2,661 shares during the period. California State Teachers Retirement System’s holdings in Bioverativ were worth $9,268,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors also recently made changes to their positions in BIVV. Wells Fargo & Company MN acquired a new position in Bioverativ in the third quarter valued at approximately $124,500,000. Jackson Square Partners LLC acquired a new position in Bioverativ in the third quarter valued at approximately $99,336,000. BlackRock Inc. lifted its holdings in Bioverativ by 16.9% in the fourth quarter. BlackRock Inc. now owns 10,845,635 shares of the biotechnology company’s stock valued at $584,795,000 after acquiring an additional 1,567,638 shares during the period. ValueAct Holdings L.P. acquired a new position in Bioverativ in the third quarter valued at approximately $72,514,000. Finally, Bank of New York Mellon Corp acquired a new position in Bioverativ in the third quarter valued at approximately $71,032,000. 97.18% of the stock is owned by institutional investors.
Shares of Bioverativ Inc (BIVV) opened at $104.98 on Monday. The company has a market capitalization of $11,360.00 and a P/E ratio of 38.31. Bioverativ Inc has a 12-month low of $48.14 and a 12-month high of $105.01.
BIVV has been the subject of a number of analyst reports. Zacks Investment Research raised Bioverativ from a “hold” rating to a “buy” rating and set a $62.00 price target for the company in a report on Monday, January 8th. William Blair reissued a “hold” rating on shares of Bioverativ in a report on Thursday, March 8th. Royal Bank of Canada boosted their price objective on Bioverativ to $68.00 and gave the company a “market perform” rating in a research report on Thursday, January 18th. Jefferies Group boosted their price objective on Bioverativ to $79.00 and gave the company a “buy” rating in a research report on Thursday, January 18th. Finally, Raymond James Financial cut Bioverativ from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 23rd. Twelve research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $63.83.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioverativ Inc (NASDAQ:BIVV).
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.